BI Asset Management Fondsmaeglerselskab A S reduced its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 47.3% during the 1st quarter, Holdings Channel.com reports. The firm owned 24,690 shares of the medical research company’s stock after selling 22,120 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Amgen were worth $5,005,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the company. Salomon & Ludwin LLC lifted its stake in shares of Amgen by 125.0% in the fourth quarter. Salomon & Ludwin LLC now owns 108 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 60 shares during the period. Savior LLC purchased a new position in Amgen in the fourth quarter valued at about $34,000. CLS Investments LLC increased its holdings in Amgen by 175.4% in the fourth quarter. CLS Investments LLC now owns 157 shares of the medical research company’s stock valued at $38,000 after buying an additional 100 shares in the last quarter. Sageworth Trust Co acquired a new stake in shares of Amgen during the 4th quarter valued at approximately $42,000. Finally, Altshuler Shaham Ltd boosted its stake in shares of Amgen by 273.9% during the 4th quarter. Altshuler Shaham Ltd now owns 172 shares of the medical research company’s stock worth $42,000 after acquiring an additional 126 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.
In other Amgen news, Director Ronald D. Sugar sold 1,000 shares of the business’s stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $233.35, for a total transaction of $233,350.00. Following the completion of the sale, the director now owns 15,636 shares of the company’s stock, valued at $3,648,660.60. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $237.31, for a total value of $100,856.75. Following the sale, the director now owns 5,834 shares of the company’s stock, valued at $1,384,466.54. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,425 shares of company stock valued at $563,477. Insiders own 0.25% of the company’s stock.
Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $4.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.70 by $0.47. Amgen had a net margin of 32.03% and a return on equity of 90.75%. The business had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $6.01 billion. During the same period last year, the company earned $3.56 earnings per share. The company’s quarterly revenue was up 10.9% on a year-over-year basis. On average, equities analysts expect that Amgen, Inc. will post 15.58 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 8th. Stockholders of record on Monday, May 18th will be paid a dividend of $1.60 per share. The ex-dividend date is Friday, May 15th. This represents a $6.40 annualized dividend and a dividend yield of 2.83%. Amgen’s dividend payout ratio is presently 43.18%.
Several equities analysts recently issued reports on the company. SVB Leerink lifted their price objective on Amgen from $219.00 to $249.00 and gave the stock a “market perform” rating in a report on Friday, May 1st. Cfra lifted their price target on Amgen from $223.00 to $259.00 and gave the stock a “buy” rating in a research note on Friday, May 1st. Robert W. Baird cut shares of Amgen from a “neutral” rating to an “underperform” rating and increased their price objective for the company from $173.00 to $185.00 in a research note on Friday, January 31st. Guggenheim began coverage on shares of Amgen in a research report on Wednesday, April 15th. They set a “neutral” rating and a $225.00 target price for the company. Finally, Wolfe Research assumed coverage on shares of Amgen in a research report on Tuesday, March 31st. They issued a “market perform” rating and a $218.00 price target on the stock. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and seventeen have issued a buy rating to the company’s stock. Amgen currently has a consensus rating of “Buy” and an average target price of $244.65.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.